Caracterização da propriedade imunoestimulatória de Virus-like particles de Triatoma virus e antígenos recombinantes quiméricos de Trypanosoma cruzi
The infection caused by the protozoan Trypanosoma cruzi affects humans and is called Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. The development of vaccines is mainly through the use of antigens of the etiol...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Dissertação |
| Idioma: | pt_BR |
| Publicado em: |
Universidade Federal do Rio Grande do Norte
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/handle/123456789/31372 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | The infection caused by the protozoan Trypanosoma cruzi affects humans and is called
Chagas disease. Currently, the main measures available to reduce the incidence of this
disease are drug treatment and vector control. The development of vaccines is mainly
through the use of antigens of the etiologic agent. Virus-like particles (VLPs) are
structures analogous to viral capsids composed essentially of structural proteins, they
have no viral genetic material and are widely used in vaccination protocols because of
their immunostimulatory properties. In this context, the objective of this study was to use
strategies in a murine immunization model to characterize the immunostimulatory
capacity of virus-like particles from Triatoma virus (VLPs-TrV), analyzed in the presence
or absence of the aluminium hydroxide vaccine adjuvant. In parallel, observing the
immunogenic behavior of four T. cruzi chimeric recombinant proteins in mix form (mixIBMP) associated or not with the VLPs-TrV. For this, BALB/c mice (Mus musculus)
were immunized once or twice, depending on the strategy, with serum samples collected
15, 30 and 45 days after the immunization. Subsequently, serum samples from animals
immunized with VLPs-TrV were obtained at different times after immunizations. The
total IgG, IgG1, IgG2a, IgG2b and IgG3 specific antibody profile was determined by
enzyme immunoassay. The data obtained demonstrate the ability of VLPs-TrV, without
the presence of aluminum, to preferably induce IgG2b and IgG3 type antibodies; in fact,
the use of aluminum did not interfere with the total IgG profile. In addition, mix-IBMP
has a better profile of total IgG and IgG1 and IgG3 subclasses when associated with
VLPs-TrV, even with the possible antigenic competition between the VLPs-TrV and
IBMP proteins. In conclusion, these results contribute to the possible use of VLPs-TrV as
an adjuvant in vaccine formulations in a murine model, although the mechanisms in
inducing the polarized cellular immune response to Th1 need to be more clearly
understood. In addition, evaluating the use of proteins in new protocols in vivo as
antigenic candidates is interesting. |
|---|